Autres domaines


Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial - 09/09/11

Doi : 10.1016/S0190-9622(98)70590-0 
Jerry Bagel, MDa, W.Thomas Garland, MDb, Debra Breneman, MDc, Michael Holick, MDd, T.W. Littlejohn, MDe, David Crosby, MDf, Holly Faust, MDg, David Fivenson, MDh, Jean Nichols, PhDi
East Windsor and Lawrenceville, New Jersey; Cincinnati, Ohio; Boston and Hopkinton, Massachusetts; Winston-Salem, North Carolina; Milwaukee, Wisconsin; Indianapolis, Indiana; and Detroit, Michigan 
From the Psoriasis Treatment Center of Central New Jersey, East Windsor a; Lawrence Clinical Research, Lawrenceville b; University Dermatology Consultants, Cincinnati c; Department of Dermatology, Boston University Medical Centerd; Department of Dermatology, Piedmont Research Associates, Winston-Salem e; Department of Dermatology, Medical College of Wisconsin, Milwaukee f; Department of Dermatology, Indiana University School of Medicine, Indianapolis g; Department of Dermatology, Henry Ford Hospital, Detroit h; and Seragen, Inc., Hopkinton. i 


Background: Current therapies for recalcitrant psoriasis focus on immunoregulation and targeting of activated T-lymphocytes rather than keratinocytes. Previous studies with low doses of the lymphocyte-selective fusion protein DAB389IL-2 have shown benefit to patients with psoriasis. Objective: We examined the safety and efficacy of DAB389IL-2 in 41 volunteers receiving more frequent and higher doses than in a previous trial. Methods: Patients were randomized to receive either placebo or 5, 10, or 15 mg/kg daily of DAB389IL-2 intravenously for 3 consecutive days each week for 4 consecutive weeks with a subsequent 4-week observation period. Results: Of the placebo group, 17% (2 of 12) exhibited at least 50% improvement from baseline Psoriasis Area and Severity Index scores at the end of the study, whereas 24% of all treated patients (7 of 29) showed the same improvement. Overall, 3 of 12 (25%) patients given placebo as opposed to 12 of 29 (41%) patients treated with DAB389IL-2 improved to this same extent at some point during the study. The rate of improvement for treated patients was significantly greater than for placebo patients (p = 0.04; repeated measures ANOVA). Among treated patients, decreases in Psoriasis Area and Severity Index scores were paralleled by changes in the Physician’s Global Assessment and the Dermatology Life Quality Index. Treatment in ten patients was discontinued because of adverse events. Flu-like symptoms were the most common with severity increasing at the two higher doses. Only one serious adverse event was reported. This occurred in a patient receiving 5 mg/kg daily who experienced vasospasm and a coagulopathy resulting in arterial thrombosis. Conclusion: Our findings are consistent with the potential antipsoriatic activity of DAB389IL-2 demonstrated in an earlier study. However, DAB389IL-2 was less well tolerated at this dosing regimen, particularly at the highest dose, and it was too toxic at these doses and schedules to be considered in the routine treatment of psoriasis. (J Am Acad Dermatol 1998;38:938-44.)

Le texte complet de cet article est disponible en PDF.


 Supported by a grant from Seragen, Inc.
 Reprint requests: Jerry Bagel, MD, Psoriasis Treatment Center of Central New Jersey, East Windsor Professional Park, Suite G, East Windsor, NJ 08520.
 0190-9622/98/$5.00 + 0   16/1/90033

© 1998  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 38 - N° 6

P. 938-944 - juin 1998 Retour au numéro
Article précédent Article précédent
  • Methyldibromoglutaronitrile (Euxyl K400): A new and important sensitizer in the United States?
  • J.Mark Jackson, Joseph F. Fowler
| Article suivant Article suivant
  • Sparfloxacin-induced photosensitivity and the occurrence of a lichenoid tissue reaction after prolonged exposure
  • Hiroko Hamanaka, Hitoshi Mizutani, Masayuki Shimizu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?


Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.